Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106


Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy.

Mora-Peris B, Watson V, Vera JH, Weston R, Waldman AD, Kaye S, Khoo S, Mackie NE, Back D, Winston A.

J Antimicrob Chemother. 2014 Jun;69(6):1642-7. doi: 10.1093/jac/dku018.


Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.

Allavena C, Dailly E, Reliquet V, Bonnet B, Pineau S, André-Garnier E, Boutoille D, Bouquié R, Raveleau A, Bouchez S, Billaud E, Raffi F.

J Antimicrob Chemother. 2014 Oct;69(10):2804-8. doi: 10.1093/jac/dku187.


The efficacy, pharmacokinetics, and safety of a nevirapine to rilpivirine switch in virologically suppressed HIV-1-infected patients.

Rokx C, Blonk M, Verbon A, Burger D, Rijnders BJ.

J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):36-9. doi: 10.1097/QAI.0000000000000363.


Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.

Gallien S, Charreau I, Nere ML, Mahjoub N, Simon F, de Castro N, Aboulker JP, Molina JM, Delaugerre C.

J Antimicrob Chemother. 2015 Feb;70(2):562-5. doi: 10.1093/jac/dku395.


Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.

Mills AM, Cohen C, Dejesus E, Brinson C, Williams S, Yale KL, Ramanathan S, Wang MH, White K, Chuck SK, Cheng AK.

HIV Clin Trials. 2013 Sep-Oct;14(5):216-23. doi: 10.1310/hct1405-216.


Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection.

Custodio JM, Yin X, Hepner M, Ling KH, Cheng A, Kearney BP, Ramanathan S.

J Clin Pharmacol. 2014 Apr;54(4):378-85. doi: 10.1002/jcph.210.


A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.

Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, Burapatarawong S, Thongyen S, Likanonsakul S, Thawornwa U, Prommool V, Ruxrungtham K; N2R Study Team..

Clin Infect Dis. 2009 Jun 15;48(12):1752-9. doi: 10.1086/599114.


Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a review of its use in HIV infection.

Deeks ED.

Drugs. 2014 Nov;74(17):2079-95. doi: 10.1007/s40265-014-0318-1. Review.


Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study.

Gantner P, Reinhart S, Partisani M, Baldeyrou M, Batard ML, Bernard-Henry C, Cheneau C, de Mautort E, Priester M, Fafi-Kremer S, Muret P, Rey D.

HIV Med. 2015 Feb;16(2):132-6. doi: 10.1111/hiv.12183.


HIV-1 CNS in vitro infectivity models based on clinical CSF samples.

Mora-Peris B, Winston A, Garvey L, Else LJ, Shattock RJ, Herrera C.

J Antimicrob Chemother. 2016 Jan;71(1):235-43. doi: 10.1093/jac/dkv326.


Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men.

Taylor S, van Heeswijk RP, Hoetelmans RM, Workman J, Drake SM, White DJ, Pillay D.

AIDS. 2000 Sep 8;14(13):1979-84.


Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.

Cohen CJ, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, Wu H, Johnson MA, Saag M, Supparatpinyo K, Crauwels H, Lefebvre E, Rimsky LT, Vanveggel S, Williams P, Boven K; ECHO Study Group.; THRIVE Study Group..

J Acquir Immune Defic Syndr. 2012 May 1;60(1):33-42. doi: 10.1097/QAI.0b013e31824d006e.


Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT, Vanveggel S, Boven K; ECHO study group..

Lancet. 2011 Jul 16;378(9787):238-46. doi: 10.1016/S0140-6736(11)60936-7.


Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).

Arasteh K, Ward D, Plettenberg A, Livrozet JM, Orkin C, Cordes C, Guo J, Wang E, Yong CL, Robinson P, Quinson A.

HIV Med. 2012 Apr;13(4):236-44. doi: 10.1111/j.1468-1293.2011.00969.x.


Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up.

Charpentier C, Lê MP, Joly V, Visseaux B, Lariven S, Phung B, Yéni P, Yazdanpanah Y, Descamps D, Peytavin G, Landman R.

PLoS One. 2015 Jul 30;10(7):e0134430. doi: 10.1371/journal.pone.0134430.


Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.

Lambert-Niclot S, Charpentier C, Storto A, Fofana D, Soulie C, Fourati S, Wirden M, Morand-Joubert L, Masquelier B, Flandre P, Calvez V, Descamps D, Marcelin AG.

J Antimicrob Chemother. 2014 Apr;69(4):1086-9. doi: 10.1093/jac/dkt463.


Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects.

Crauwels H, Vingerhoets J, Ryan R, Witek J, Anderson D.

Antivir Ther. 2012;17(3):439-46. doi: 10.3851/IMP1959.


Presence of Tablet Remnants of Nevirapine Extended-Release in Stools and Its Impact on Virological Outcome in HIV-1-Infected Patients: A Prospective Cohort Study.

Lee YC, Lin SW, Chen MY, Chang SY, Kuo CH, Sheng WH, Hsieh SM, Sun HY, Chang HY, Wu MR, Liu WC, Wu PY, Yang SP, Zhang JY, Su YC, Luo YZ, Hung CC, Chang SC.

PLoS One. 2015 Oct 14;10(10):e0140574. doi: 10.1371/journal.pone.0140574.


Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.

Tiraboschi JM, Muñoz-Moreno JA, Puertas MC, Alonso-Villaverde C, Prats A, Ferrer E, Rozas N, Maso M, Ouchi D, Martinez-Picado J, Podzamczer D.

HIV Med. 2015 Jul;16(6):388-92. doi: 10.1111/hiv.12243.

Items per page

Supplemental Content

Support Center